Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FOXO3
REST API REST API
Homo sapiens
FOXO3 is differentially expressed in 347 experiments: 135 organism parts: bone marrow, cerebellum, ... (133 more);, 221 disease states: normal, cervical carcinoma, ... (219 more);, 116 cell types 464 cell lines 48 compound treatments and 84 other conditions.
Synonyms AF6q21, FKHRL1, FOXO2, FOXO3A
Orthologs Foxo3 (Mus musculus)   foxo (Drosophila melanogaster)   FOXO3 (Bos taurus)   FOXO3 (Gallus gallus)   foxo3a (Danio rerio)   foxo3b (Danio rerio)   Foxo3 (Rattus norvegicus)   ENSCING00000016777 (Ciona intestinalis)   ENSCING00000016781 (Ciona intestinalis)   foxo3 (Xenopus laevis)   FOXO3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, pattern specification process, embryo development, DNA binding, protein binding, apoptosis, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, regulation of cell proliferation, transcription, DNA-dependent, DNA bending activity, insulin receptor signaling pathway, membrane fraction, glucose homeostasis, fibroblast growth factor receptor signaling pathway, transcription factor binding, DNA damage response, signal transduction by p53 class mediator, sequence-specific DNA binding, induction of apoptosis, positive regulation of transcription from RNA polymerase II promoter, tissue development, protein kinase binding, nucleus, oocyte maturation, transcription factor complex, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, response to DNA damage stimulus, positive regulation of transcription, DNA-dependent, positive regulation of erythrocyte differentiation, ovulation from ovarian follicle, nerve growth factor receptor signaling pathway, antral ovarian follicle growth, initiation of primordial ovarian follicle growth, sequence-specific DNA binding transcription factor activity, phosphatidylinositol-mediated signaling, regulation of sequence-specific DNA binding transcription factor activity, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term TF_fork_head
UniProt Accession O43524, B4DVZ6, F5H7C9
Search EB-eye ENSG00000118689
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-4717, E-GEOD-2450, ... (42 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
A549
2
E-GEOD-3202, E-GEOD-6013
BT20
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
MCF-7
1
2
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
GM08388
1
E-TABM-321
458 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-20677, E-TABM-34, E-GEOD-2822, E-GEOD-21909, ... (53 experiments)

Factor Value U/D Experiments
embryonic stem cell
1
2
E-GEOD-26672, E-MEXP-930, E-GEOD-2248
macrophage
1
2
E-GEOD-22373, E-GEOD-360, E-GEOD-5099
articular cartilage
1
E-MEXP-2488
epidermal keratinocyte
1
E-GEOD-2822
CD4 positive T-cell
1
E-GEOD-6338
CD326negCD56+ cell
1
E-GEOD-21668
110 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (76 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MEXP-231, E-MTAB-37, E-MTAB-62
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
prostate carcinoma
3
E-MTAB-62, E-GEOD-96, E-GEOD-5377
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-16728
cervical carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-5823, E-MEXP-1331
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
215 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (30 experiments)

Factor Value U/D Experiments
none
4
8
E-MEXP-1601, E-GEOD-20719, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (12 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
NaOH
1
E-MEXP-2590
PGE2
1
E-MEXP-1230
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
BCR/FGFR1
1
1
E-GEOD-15811
42 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1140, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-1751, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-TABM-36, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-10315, E-GEOD-837, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (42 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290

Vehicle
studied in E-GEOD-5258

Processing time: 0.344 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM